Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

@article{Mcinnes2013EfficacyAS,
  title={Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.},
  author={Iain B. Mcinnes and Arthur J Kavanaugh and Alice Bendix Gottlieb and L Gonz{\'a}lez Puig and Proton Rahman and Christopher J Ritchlin and Carrie Brodmerkel and Shu Zhen Li and Yuhua Wang and Alan M. Mendelsohn and Mittie K Doyle},
  journal={Lancet},
  year={2013},
  volume={382 9894},
  pages={780-9}
}
BACKGROUND Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody ustekinumab is an efficacious treatment for moderate-to-severe plaque psoriasis. We did a randomised, placebo-controlled, phase 3 trial to assess the safety and efficacy of ustekinumab in patients with active psoriatic arthritis. METHODS In this phase 3, multicentre, double-blind, placebo… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 15 times over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com